Kornimate/medical-research-clean huggingface dataset:
autologous bone marrow derived stem cells in decompensate cirrhotic patients

Conditions: Liver Cirrhosis

Summary: liver cirrhosis (lc) is the final outcome for chronic liver diseases. the liver transplantation is the sole effective therapy available to these patients. however, limited number of donors, post surgical complications, immunological rejection, and financial consideration are it's crucial problems. the plasticity of stem cells in bone marrow (bm) to differentiate into hepatocyte cells was recently confirmed, and several clinical studies have applied bmc injection to induce regeneration of myocardium and blood vessels. in this study, the investigators will study safety and feasibility of twice transplantation of autologous bone derived marrow mono nuclear (bm-mnc) and enriched cd133+ hematopoietic stem cell through the portal vein in patients with decompensate cirrhosis.

bm aspiration will be done twice (3months interval) from the iliac crest according to standard procedures under general anesthesia and is collected (200ml) in plastic bags containing anti coagulant. after precipitation of red blood cells, mononuclear cells will be collected by centrifugation in ficoll-paque density gradient. for separation of cd133+ cells the clinimacs instrument will be used. cells are injected twice (3months interval) via portal vein under sonography monitoring. after cell therapy, patients are followed up every week for 6 months, and laboratory data are analyzed for 6 months

Eligibility criteria:
inclusion criteria: * 16-65 years cirrhotic patient * approved cirrhosis by elastografy ,biopsy, sonography * serum alt 1/5 times more than normal * meld score 12 or child score b or c exclusion criteria: * portal vein thrombosis * hepatic encephalopathy, score 3\&4 * alt \& ast 3times more than normal * serum cr more than 1/5mg/dl * (anti-hiv +) (anti-hcv+) (hbs-ag+) * hepatocel carcinoma * primary sclerosing cholangitis (psc) * esophageal varices grade 4 * addiction

Keywords: cirrhotic stem cells bone marrow stem cells decompensate cirrhotic patients
the effects of oxycodone versus sufentanil on pain and inflammatory response after tace

Conditions: Hepatocellular Carcinoma; Transcatheter Arterial Chemoembolization; Pain; Inflammation

Summary: the purpose of this randomized, double-blind trial was to compare the effects of preemptive oxycodone and sufentanil at the same dose on pain and inflammatory response after transcatheter arterial chemoembolization (tace) of hepatocellular carcinoma. to study the effect of single dose intravenous injection of oxycodone and sufentanil before tace on inflammatory reaction after tace; and (ii) evaluate the effects of different opioid drugs on pain and nausea/vomiting after tace.

transcatheter arterial chemoembolization (tace) is currently considered as the treatment for unresectable hepatocellular carcinoma (hcc). due to sudden blockage of the main blood vessels supplying the tumor, local liver tissue swells and the tumor rapidly necroses. a large number of inflammatory mediators, including white blood cell (wbc) count, c-reactive protein (crp) and interleukin 6 (il-6), will inevitably appear in tace induced ischemic and/or necrotic tissue reactions, which contribute to the development of pain. pain can worsen the patient's quality of life, prolong hospital stay, and increase costs. 93% of patients require opioid therapy during and after tace. opioids are the most common drugs for treating pain. there are three types of opioid receptors, μ receptors κ receptors and δ receptors. sufentanil is a highly selective drug μ receptor agonists have fast onset and strong analgesic effects. however, sufentanil is not as effective as oxycodone in relieving visceral pain. oxycodone not only activates μ receptors, also occupying κ receptors, alleviate visceral ischemic pain and inflammatory reactions. in addition to the type of medication, the administration time can also affect perioperative pain. preemptive analgesia refers to the intervention of pain relief before nociceptive stimuli to suppress the progression of stress states and central sensitization.

Eligibility criteria:
inclusion criteria: * age ≥18 years; * presence of histologically confirmed or clinically diagnosed hepatocellular carcinoma (fulfilling the criteria for lesions with typical imaging); * presence of child-pugh class a or b disease; * absence of benefit from a treatment of established efficacy such as resection and local ablation; * ecog:0-2. exclusion criteria: * extrahepatic metastasis and/or microvascular invasion; * severe liver and kidney dysfunction; * uncontrolled or significant cardiovascular disease; autoimmune hepatitis; long term use of opioids, steroid hormones, and non steroidal anti-inflammatory drugs; abnormal elevation of c-reactive protein (crp); increased white blood cells (\>11000/mm3); study drugs allergy; patients who were treated within 4 weeks after covid-19 infection was diagnosed.
sphenopalatine ganglion block with bupivacaine and its effect on pain after functional endoscopic sinus surgery

Conditions: Anaesthesia

Summary: functional endoscopic sinus surgery (fess) is a minimally invasive procedure that is used in many inflammatory and infectious sinus diseases. acute postoperative pain can lead to adverse consequences and good postoperative treatment of pain is essential. there is no agreement on a single protocol to treat pain after endoscopic sinus surgeries, and the usually used analgesics have some side effects that hinder their use. current evidence is insufficient for routine clinical use of the sphenopalatine ganglion block for functional endoscopic sinus surgery and the efficacy of sphenopalatine ganglion block for pain control after functional endoscopic sinus surgery remains controversial. this study aims to explore the influence of sphenopalatine ganglion block on pain intensity after functional endoscopic sinus surgery by comparing two groups, a group receiving the block with bupivacaine injection, versus saline injection in the other group.


Eligibility criteria:
inclusion criteria: 1. age: 18 years - 80 years. 2. asa i and asa ii patients. 3. consented to participate in the research. exclusion criteria: 1. pregnant and breastfeeding females. 2. history of allergy to bupivacaine or other local anaesthetics. 3. patients with uncontrolled hypertension, poorly controlled cardiovascular diseases, or cerebrovascular diseases. 4. patients with pre-existing neurological conditions. 5. patients with history of alcohol or drug abuse. 6. patients on anticoagulation. 7. occurrence of surgical or anaesthetic complications or change in the anaesthesia protocol. 8. patients showing sensitivity to bupivacaine. 9. patients unable to understand vas score. 10. patients refusing to continue participating in the study.
endoscopic bariatric stapling pilot study

Conditions: Obesity

Summary: this study is a prospective single-arm, multicenter study to evaluate the safety and effectiveness of the toga® procedure for the treatment of morbid obesity.


Eligibility criteria:
inclusion criteria: 1. age 18 years - 60 years 2. eligible for bariatric surgery per us national institute of health (nih) guidelines bmi ≥ 40 kg/m2 and \< 55 kg/m2, or bmi ≥ 35 kg/m2 with one or more comorbidities. comorbidities are defined as diabetes, pulmonary disease, cardiac disease, or hypertension \[systolic blood pressure of ≥140 mm hg or diastolic blood pressure ≥ 90 mm hg (or both) or on treatment for hypertension\] 3. history of obesity for at least 2.5 years 4. history of failure with non-surgical weight loss methods. 5. agree to comply with the substantial dietary restrictions required by the procedure. 6. understands risks of procedures, agree to follow protocol requirements, including signing informed consent, returning for follow-up visits and completing all required testing, completing diet and behavior modification counseling. exclusion criteria: 1. patient history of inflammatory disease of the gastrointestinal tract including crohn's disease or ulcerative colitis. 2. significant known esophageal disease including grade 3-4 esophagitis, stricture, barrett's esophagus, esophageal cancer, esophageal diverticulum, nutcracker esophagus, achalasia, esophageal dysmotility. 3. severe coagulopathy, upper gi bleeding conditions such as esophageal or gastric varices, congenital or acquired telangiectasia. 4. congenital or acquired anomalies of the gi tract such as atresias or stenoses. 5. hiatal hernia ≥2cm 6. severe cardiopulmonary disease or other serious organic disease including hiv or cancer. 7. currently pregnant or nursing. potentially childbearing (i.e not post-menopausal or surgically sterilized) and not willing to use an effective method of contraception for the next 12 months. 8. current alcohol or drug addiction. 9. mentally retarded or emotionally unstable, or exhibits psychological characteristics which, in the opinion of the investigator or psychologist/psychiatrist, make the subject a poor candidate for this procedure. 10. previous gastric, esophageal, pancreatic, or bariatric surgery. 11. infection anywhere in the body at the time of the procedure. 12. patient history of scleroderma. 13. thyroid disease which is not controlled with medication. 14. participating in another ongoing clinical trial in which concomitant diagnosis or therapeutic intervention would adversely affect the integrity of the clinical trial. 15. known active h-pylori infection.
prothrombin complex concentrate vs fresh frozen plasma in goal-directed bleeding management in cardiac surgery

Conditions: Cardiac Valve Disease

Summary: the primary endpoint of this study is the completion time of hemostasis treatment when administered fresh frozen plasma (ffp) and frozen powder coagulation factor concentrate (pcc) in goal-directed bleeding management for cardiac surgery.


Eligibility criteria:
inclusion criteria: * patients undergoing cardiac surgery exclusion criteria: * thrombocytopenia * oral anti-coagulant * anti platelet agents
mbct-t for preoperative pain catastrophizing and pain outcomes after spine surgery

Conditions: Pain

Summary: this is a two phase study. in phase 1, a focus group (n=5) will be conducted to adapt mbct-t for use in the study population. in phase 2, a single-arm trial will be conducted examining four, weekly sessions of preoperative mbct-t in subjects with high pain catastrophizing scheduled for spine surgery (n=20). subjects will then be followed for two weeks postoperatively.


Eligibility criteria:
inclusion criteria: * scheduled for one or two level lumbar spine surgery requiring an inpatient stay as well as patients having ambulatory 1 or 2 level lumbar spine surgeries * pcs score ≥ 20 * able to provide voluntary informed consent * telephone access * internet access exclusion criteria: * non-english speaking * cognitively impaired, by history * bipolar disorder * borderline personality disorder * active post-traumatic stress disorder * schizoaffective disorder or any other disorder characterized by delusions or hallucinations * history of self-harm or suicidality in past three months
ultrasound-guided blood sampling with a sterile and dry puncture area

Conditions: Ultrasound; Sterile Puncture Area; Blood Sampling

Summary: thousands of vein punctures are done every day at hospitals worldwide. vein puncture are performed in connection with blood sampling, peripheral intravenous catheter (piv) placement or blood donation. the predominantly used venous for blood withdraw are in the cubital region because in this area venous are most superficial placed and most often visible for the human eye. however, when using the usual blind landmark and palpation method in this region, it often proves exceedingly difficult or even impossible to obtain peripheral venous access on patients who are obese, chronically ill, hypovolemic or intravenous drug users. various studies have shown that the success rate for establishing a vascular access with ultrasound compared to blind landmark technique is higher in patients with difficult access. when ultrasound is used to establish intravascular access, the prerequisite sterile puncture area can be challenging to meet due to ultrasound gel on the area and the fact that the ultrasound transducer cannot be wiped clean with alcohol after being in contact with a patient's skin or blood. a strict sterile procedure is important to reduce complications related to infection.the traditional way of coping with this is by covering the transducer and the wire in a long sterile sheet and using sterile gel. the sheet must be tight with rubber band around the transducer and pulled tightly around the transducer foot to prevent artefacts from appearing on the screen. this is an expensive and time consuming method, and it still leaves the problem with gel in the puncture area. the investigators have developed a method by where all these problems are solved by using, a slightly modified, commercial drape in combination with the dynamic needle tip positioning technique the investigators hypothesize that it is possible to perform ultrasound-guided venous puncture with a sterile and dry puncture area and that puncture can be performed proximal and distal to the traditional puncture side. it is a procedure presenting study that serves to demonstrate the feasibility of the method in ten healthy volunteers. the study will take place at aarhus university hospital, skejby.


Eligibility criteria:
inclusion criteria: * age between 18 and 70 years of age * mentally competent * of good health exclusion criteria: * age below 18 or above 70 years of age * daily use of blood thinner medication * suffering from a chronic illness that requires frequent blood withdrawals * heart conditions or vascular diseases * people known to experience vasovagal episodes when having blood samples taken
anticipatory guidance to prevent childhood obesity

Conditions: Childhood Obesity

Summary: the purpose of this pilot project is to test anticipatory guidance, which is information given to families during a well child visit to prevent obesity during childhood. the objectives were to compare two styles of anticipatory guidance during the first year of life, maternal focused and infant focused, versus usual care and determine which style, if any, showed the most ideal infant feeding behaviors at age 1 year and to see if there were any differences in infant weight for height at one year of age. the investigators hypothesized that mothers who received the maternal focused anticipatory guidance (which gave information on eating family meals, not having tv on during meals, and maternal nutrition) would actually have the best infant feeding behaviors and weight for height of infants at one year.


Eligibility criteria:
inclusion criteria: maternal/infant pairs infant under 2 months of age mother english speaking exclusion criteria: history of neonatal icu stay in infant gestation less than 37 weeks in infant chronic disease in infant known genetic disorder in infant foster care placement in infant

Keywords: well child visit anticipatory guidance obesity prevention infant feeding
clinical trial of car-t in the treatment of relapsed and refractory hematopoietic and lymphoid tissue tumors in children

Conditions: Leukemia; Lymphoma

Summary: this is an open, single-arm, prospective，clinical study to evaluate efficacy and safety of auto car-t cell injection in the treatment of recurrent or refractory hematopoietic and lymphoid tissue tumors in children

a single car consists of scfv, hinge region, transmembrane region, costimulatory domain and zeta subunit of cd3.prior to car-t cell infusion, the patients will be subjected to preconditioning treatment. after car-t cell infusion, the patients will be evaluated for adverse reactions and efficacy.

Eligibility criteria:
inclusion criteria: 1. sign the informed consent and be willing and able to comply with the visit, treatment regimen, laboratory examination and other requirements of the study as stipulated in the trial flow chart; 2. patients with relapsed and refractory hematopoiesis and lymphoid tissue tumors confirmed by clinical diagnosis; 3. age: 1-18 years (including boundary value), both male and female; 4. subjects with lansky score ≥ 50; 5. the results of treatment-related antigens were positive; 6. the expected survival time is more than 3 months from the date of signing the informed consent. exclusion criteria: 1. severe cardiac insufficiency and left ventricular ejection fraction \< 50%; 2. he had a history of severe lung function damage; 3. combined with other advanced malignant tumors; 4. severe infection was found and could not be effectively controlled; 5. with metabolic diseases (except diabetes mellitus); 6. combined with severe autoimmune disease or congenital immunodeficiency; 7. untreated active hepatitis (hepatitis b, defined as positive hbsag, hbv-dna ≥ 500 iu / ml and abnormal liver function; hepatitis c, defined as hepatitis c antibody \[hcv ab\] positive, hcv-rna higher than the detection limit of the analysis method and abnormal liver function) or combined with hepatitis b and hepatitis c co infection; 8. human immunodeficiency virus (hiv) infection or known acquired immunodeficiency syndrome (aids), or syphilis infection; 9. severe allergy history of biological products (including antibiotics); 10. patients with acute graft-versus-host reaction (gvhd) after one month of discontinuation of immunosuppressants were still present; 11. the presence of other serious physical or mental illness or laboratory abnormalities that may increase the risk of participating in the study, or interfere with the results of the study, and patients considered unsuitable for the study by the investigator.
effects of high caffeine content coffee on blood pressure in young adults

Conditions: High Blood Pressure

Summary: the purpose of this study is to help further the understanding of the effects of commercially available high-caffeine containing coffee on blood pressure in healthy adult subjects.


Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years old * male or female * no prior diagnosis of hypertension * no prior chronic disease requiring medical intervention * ability to demonstrate correct usage of ambulatory blood pressure monitoring device exclusion criteria: - age less than 18 years old * prior chronic disease (such as hypertension) requiring medical intervention * previously undiagnosed hypertension * intolerance or allergy to coffee or caffeine * inability to demonstrate correct usage of ambulatory blood pressure monitoring device * inability to complete the required abstinence period prior to study interventions * known pregnancy * use of birth control * tobacco use * participation in other investigational drug studies at the time of this study * medical illness requiring medical or symptomatic management
the level of blood brain barrier damage biomarker in acute ischemic stroke

Conditions: Ischemic Stroke

Summary: hemorrhagic transformation is a common complication of acute ischemic stroke patients . bbb damage is regarded as a major pathophysiological mechanism of hemorrhagic transformation. so, the investigators hypothesis the level of bbb damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

hemorrhagic transformation is a common complication of acute ischemic stroke patients . bbb injury often occurs in the early stage of ischemic stroke, leading brain tissue edema or even hemorrhagic transformation with the development of ischemic injury. the biomarker of bbb damage, such as the level of serum occludin, can reflect the extent of bbb injury. so, the investigators hypothesis the level of bbb damage biomarker is predictor of intracranial hemorrhage following ischemic stroke.

Eligibility criteria:
inclusion criteria: 1. enrolled patients aged 18-80years. 2. acute ischemic stroke 3. informed consent obtained. exclusion criteria: 1. tumor stroke or hemorrhagic stroke or hemorrhagic cerebral infarction on admission. 2. stroke or serious head trauma within the previous 3 months 3. inflammatory or infectious diseases, cancer, coagulation disturbance disease and severe renal and liver failure 4. blood sample occurred hemolysis or cloudy. 5. incomplete clinical data 6. platelet count of less than 100,000 per cubic millimeter 7. received oral anticoagulation therapy preceding the onset of stroke and inr greater than 1.7 or prothrombin times greater than 15 seconds 8. pregnant or breast-feeding women 9. patients being enrolled or having been enrolled in other clinical trial -

Keywords: blood brain barrier hemorrhagic transformation ischemic stroke
high vs normal protein diets, resistance exercise, lean mass and strength gains

Conditions: Sarcopenia

Summary: this study evaluates the effect of different types of diets (high and normal protein) on lean and fat mass, and strength in postmenopausal women practitioners of resistance exercise. two groups will be created: high protein (1.2 protein g/body mass/day) and normal protein (0.8 protein g/body mass/day). the same training will be performed for both groups.

both groups will undergo the same training protocol, differing only on the protein content of the diet. the dietary assessment will be made through the 24-hour food recall, being conducted at the beginning, middle and end of the intervention. resistance exercises for upper and lower limbs will be performed, at 70% of one repetition maximum. sppb, tug, 6-minutes and 400 meters will be performed.

Eligibility criteria:
inclusion criteria: * women in the postmenopausal period (menopausal for at least one year, confirmed by laboratory diagnostic tests menopause - lh and high fsh and estradiol decreased); * healthy; * who agree to participate and sign the consent term. exclusion criteria: * the one who does not provide the necessary information for the development of the study; * present orthopedic limitations; * patients with previously diagnosed and treatment of diseases such as type ii diabetes mellitus, hypertension and cardiovascular disease.

Keywords: lean mass postmenopausal protein